nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—CSF1R—atherosclerosis	0.333	1	CbGaD
Pazopanib—UGT1A1—Ezetimibe—atherosclerosis	0.0387	0.0946	CbGbCtD
Pazopanib—UGT1A1—Simvastatin—atherosclerosis	0.036	0.0879	CbGbCtD
Pazopanib—UGT1A1—Lovastatin—atherosclerosis	0.0352	0.086	CbGbCtD
Pazopanib—SLCO1B1—Rosuvastatin—atherosclerosis	0.0268	0.0655	CbGbCtD
Pazopanib—SLCO1B1—Ezetimibe—atherosclerosis	0.0268	0.0655	CbGbCtD
Pazopanib—SLCO1B1—Simvastatin—atherosclerosis	0.0249	0.0609	CbGbCtD
Pazopanib—SLCO1B1—Pravastatin—atherosclerosis	0.0244	0.0596	CbGbCtD
Pazopanib—SLCO1B1—Lovastatin—atherosclerosis	0.0244	0.0596	CbGbCtD
Pazopanib—ABCG2—Ezetimibe—atherosclerosis	0.0213	0.052	CbGbCtD
Pazopanib—ABCG2—Rosuvastatin—atherosclerosis	0.0213	0.052	CbGbCtD
Pazopanib—ABCG2—Pravastatin—atherosclerosis	0.0194	0.0473	CbGbCtD
Pazopanib—CYP2C8—Simvastatin—atherosclerosis	0.0105	0.0258	CbGbCtD
Pazopanib—CYP2C8—Pravastatin—atherosclerosis	0.0103	0.0252	CbGbCtD
Pazopanib—CYP2C8—Lovastatin—atherosclerosis	0.0103	0.0252	CbGbCtD
Pazopanib—CYP2D6—Niacin—atherosclerosis	0.00851	0.0208	CbGbCtD
Pazopanib—ABCB1—Ezetimibe—atherosclerosis	0.00768	0.0188	CbGbCtD
Pazopanib—ABCB1—Simvastatin—atherosclerosis	0.00714	0.0174	CbGbCtD
Pazopanib—ABCB1—Pravastatin—atherosclerosis	0.00698	0.0171	CbGbCtD
Pazopanib—ABCB1—Lovastatin—atherosclerosis	0.00698	0.0171	CbGbCtD
Pazopanib—CYP2D6—Simvastatin—atherosclerosis	0.00672	0.0164	CbGbCtD
Pazopanib—CYP2D6—Pravastatin—atherosclerosis	0.00658	0.0161	CbGbCtD
Pazopanib—CYP2D6—Lovastatin—atherosclerosis	0.00658	0.0161	CbGbCtD
Pazopanib—STK10—renal artery—atherosclerosis	0.00565	0.0856	CbGeAlD
Pazopanib—CYP3A4—Ezetimibe—atherosclerosis	0.0046	0.0112	CbGbCtD
Pazopanib—CYP3A4—Rosuvastatin—atherosclerosis	0.0046	0.0112	CbGbCtD
Pazopanib—CYP3A4—Simvastatin—atherosclerosis	0.00428	0.0104	CbGbCtD
Pazopanib—CYP3A4—Lovastatin—atherosclerosis	0.00418	0.0102	CbGbCtD
Pazopanib—CYP3A4—Pravastatin—atherosclerosis	0.00418	0.0102	CbGbCtD
Pazopanib—FGFR3—appendage—atherosclerosis	0.00269	0.0407	CbGeAlD
Pazopanib—PDGFRA—penis—atherosclerosis	0.00236	0.0357	CbGeAlD
Pazopanib—FLT1—umbilical vein—atherosclerosis	0.00207	0.0315	CbGeAlD
Pazopanib—FGF1—appendage—atherosclerosis	0.00186	0.0282	CbGeAlD
Pazopanib—KDR—umbilical vein—atherosclerosis	0.00175	0.0266	CbGeAlD
Pazopanib—KDR—hindlimb—atherosclerosis	0.00161	0.0243	CbGeAlD
Pazopanib—KDR—appendage—atherosclerosis	0.00138	0.0209	CbGeAlD
Pazopanib—FGF1—artery—atherosclerosis	0.00133	0.0202	CbGeAlD
Pazopanib—FLT4—endothelium—atherosclerosis	0.00126	0.0192	CbGeAlD
Pazopanib—FLT4—blood vessel—atherosclerosis	0.00117	0.0177	CbGeAlD
Pazopanib—FLT1—artery—atherosclerosis	0.00116	0.0177	CbGeAlD
Pazopanib—FGF1—endothelium—atherosclerosis	0.00112	0.017	CbGeAlD
Pazopanib—FGF1—blood vessel—atherosclerosis	0.00104	0.0157	CbGeAlD
Pazopanib—KDR—artery—atherosclerosis	0.000984	0.0149	CbGeAlD
Pazopanib—FLT1—endothelium—atherosclerosis	0.000983	0.0149	CbGeAlD
Pazopanib—FLT1—blood vessel—atherosclerosis	0.000907	0.0138	CbGeAlD
Pazopanib—KDR—endothelium—atherosclerosis	0.000831	0.0126	CbGeAlD
Pazopanib—ITK—adipose tissue—atherosclerosis	0.00082	0.0124	CbGeAlD
Pazopanib—SH2B3—cardiovascular system—atherosclerosis	0.000797	0.0121	CbGeAlD
Pazopanib—LYN—connective tissue—atherosclerosis	0.00077	0.0117	CbGeAlD
Pazopanib—KDR—blood vessel—atherosclerosis	0.000767	0.0116	CbGeAlD
Pazopanib—FGFR3—connective tissue—atherosclerosis	0.000766	0.0116	CbGeAlD
Pazopanib—TAOK1—adipose tissue—atherosclerosis	0.000746	0.0113	CbGeAlD
Pazopanib—KIT—endothelium—atherosclerosis	0.000737	0.0112	CbGeAlD
Pazopanib—SH2B3—adipose tissue—atherosclerosis	0.000702	0.0107	CbGeAlD
Pazopanib—MAP3K9—liver—atherosclerosis	0.000697	0.0106	CbGeAlD
Pazopanib—KIT—blood vessel—atherosclerosis	0.000679	0.0103	CbGeAlD
Pazopanib—PDGFRB—blood vessel—atherosclerosis	0.000664	0.0101	CbGeAlD
Pazopanib—STK16—adipose tissue—atherosclerosis	0.000597	0.00906	CbGeAlD
Pazopanib—RIOK2—adipose tissue—atherosclerosis	0.000588	0.00892	CbGeAlD
Pazopanib—BMPR1B—adipose tissue—atherosclerosis	0.000582	0.00883	CbGeAlD
Pazopanib—MAP3K2—connective tissue—atherosclerosis	0.000564	0.00855	CbGeAlD
Pazopanib—FGF1—connective tissue—atherosclerosis	0.000531	0.00805	CbGeAlD
Pazopanib—STK36—adipose tissue—atherosclerosis	0.000528	0.00801	CbGeAlD
Pazopanib—TAOK1—liver—atherosclerosis	0.000523	0.00793	CbGeAlD
Pazopanib—FLT4—cardiovascular system—atherosclerosis	0.00052	0.00789	CbGeAlD
Pazopanib—PI4KB—adipose tissue—atherosclerosis	0.00052	0.00789	CbGeAlD
Pazopanib—LIMK2—adipose tissue—atherosclerosis	0.000511	0.00774	CbGeAlD
Pazopanib—FGFR2—connective tissue—atherosclerosis	0.000502	0.00761	CbGeAlD
Pazopanib—SH2B3—liver—atherosclerosis	0.000493	0.00747	CbGeAlD
Pazopanib—FLT1—connective tissue—atherosclerosis	0.000465	0.00705	CbGeAlD
Pazopanib—FGF1—cardiovascular system—atherosclerosis	0.000462	0.00701	CbGeAlD
Pazopanib—FLT4—adipose tissue—atherosclerosis	0.000459	0.00696	CbGeAlD
Pazopanib—PIP4K2C—adipose tissue—atherosclerosis	0.000456	0.00692	CbGeAlD
Pazopanib—FGFR1—adipose tissue—atherosclerosis	0.000453	0.00686	CbGeAlD
Pazopanib—TAOK3—connective tissue—atherosclerosis	0.000438	0.00665	CbGeAlD
Pazopanib—FGFR2—cardiovascular system—atherosclerosis	0.000436	0.00662	CbGeAlD
Pazopanib—PDGFRA—connective tissue—atherosclerosis	0.000436	0.00661	CbGeAlD
Pazopanib—MAP3K2—adipose tissue—atherosclerosis	0.000433	0.00656	CbGeAlD
Pazopanib—STK16—liver—atherosclerosis	0.000419	0.00635	CbGeAlD
Pazopanib—LYN—liver—atherosclerosis	0.000415	0.00628	CbGeAlD
Pazopanib—FGFR3—liver—atherosclerosis	0.000412	0.00625	CbGeAlD
Pazopanib—RIOK2—liver—atherosclerosis	0.000412	0.00625	CbGeAlD
Pazopanib—FGF1—adipose tissue—atherosclerosis	0.000408	0.00618	CbGeAlD
Pazopanib—LCK—adipose tissue—atherosclerosis	0.000405	0.00614	CbGeAlD
Pazopanib—FLT1—cardiovascular system—atherosclerosis	0.000405	0.00613	CbGeAlD
Pazopanib—KDR—connective tissue—atherosclerosis	0.000393	0.00596	CbGeAlD
Pazopanib—FGFR2—adipose tissue—atherosclerosis	0.000385	0.00584	CbGeAlD
Pazopanib—CSF1R—connective tissue—atherosclerosis	0.000384	0.00582	CbGeAlD
Pazopanib—STK10—cardiovascular system—atherosclerosis	0.000383	0.00581	CbGeAlD
Pazopanib—TAOK3—cardiovascular system—atherosclerosis	0.000382	0.00578	CbGeAlD
Pazopanib—PDGFRA—cardiovascular system—atherosclerosis	0.000379	0.00575	CbGeAlD
Pazopanib—STK36—liver—atherosclerosis	0.00037	0.00562	CbGeAlD
Pazopanib—PI4KB—liver—atherosclerosis	0.000365	0.00553	CbGeAlD
Pazopanib—LIMK2—liver—atherosclerosis	0.000358	0.00543	CbGeAlD
Pazopanib—FLT1—adipose tissue—atherosclerosis	0.000357	0.00541	CbGeAlD
Pazopanib—EPHB6—adipose tissue—atherosclerosis	0.000353	0.00535	CbGeAlD
Pazopanib—KIT—connective tissue—atherosclerosis	0.000348	0.00528	CbGeAlD
Pazopanib—Liver function test abnormal—Niacin—atherosclerosis	0.000346	0.00421	CcSEcCtD
Pazopanib—Pancreatitis—Simvastatin—atherosclerosis	0.000346	0.00421	CcSEcCtD
Pazopanib—Photosensitivity reaction—Lovastatin—atherosclerosis	0.000344	0.00419	CcSEcCtD
Pazopanib—Dry skin—Niacin—atherosclerosis	0.000343	0.00418	CcSEcCtD
Pazopanib—KDR—cardiovascular system—atherosclerosis	0.000342	0.00519	CbGeAlD
Pazopanib—MAP2K5—cardiovascular system—atherosclerosis	0.000342	0.00519	CbGeAlD
Pazopanib—Liver function test abnormal—Pravastatin—atherosclerosis	0.000341	0.00415	CcSEcCtD
Pazopanib—PDGFRB—connective tissue—atherosclerosis	0.00034	0.00516	CbGeAlD
Pazopanib—Dry skin—Pravastatin—atherosclerosis	0.000338	0.00412	CcSEcCtD
Pazopanib—STK10—adipose tissue—atherosclerosis	0.000338	0.00512	CbGeAlD
Pazopanib—Photosensitivity reaction—Ezetimibe—atherosclerosis	0.000337	0.00411	CcSEcCtD
Pazopanib—TAOK3—adipose tissue—atherosclerosis	0.000336	0.0051	CbGeAlD
Pazopanib—PDGFRA—adipose tissue—atherosclerosis	0.000334	0.00507	CbGeAlD
Pazopanib—CSF1R—cardiovascular system—atherosclerosis	0.000334	0.00506	CbGeAlD
Pazopanib—Nasopharyngitis—Pravastatin—atherosclerosis	0.00033	0.00402	CcSEcCtD
Pazopanib—Infestation—Ezetimibe—atherosclerosis	0.00033	0.00401	CcSEcCtD
Pazopanib—Infestation NOS—Ezetimibe—atherosclerosis	0.00033	0.00401	CcSEcCtD
Pazopanib—Abdominal distension—Niacin—atherosclerosis	0.000326	0.00397	CcSEcCtD
Pazopanib—Alanine aminotransferase increased—Pravastatin—atherosclerosis	0.000325	0.00396	CcSEcCtD
Pazopanib—Photosensitivity reaction—Simvastatin—atherosclerosis	0.000322	0.00392	CcSEcCtD
Pazopanib—FLT4—liver—atherosclerosis	0.000322	0.00488	CbGeAlD
Pazopanib—Jaundice—Ezetimibe—atherosclerosis	0.000321	0.00391	CcSEcCtD
Pazopanib—Abdominal distension—Pravastatin—atherosclerosis	0.000321	0.00391	CcSEcCtD
Pazopanib—PIP4K2C—liver—atherosclerosis	0.00032	0.00485	CbGeAlD
Pazopanib—FGFR1—liver—atherosclerosis	0.000317	0.00481	CbGeAlD
Pazopanib—Pancreatitis—Pravastatin—atherosclerosis	0.000313	0.00381	CcSEcCtD
Pazopanib—Mental disorder—Rosuvastatin—atherosclerosis	0.000312	0.0038	CcSEcCtD
Pazopanib—Hepatobiliary disease—Ezetimibe—atherosclerosis	0.000312	0.0038	CcSEcCtD
Pazopanib—Jaundice—Simvastatin—atherosclerosis	0.000306	0.00373	CcSEcCtD
Pazopanib—Flatulence—Rosuvastatin—atherosclerosis	0.000305	0.00372	CcSEcCtD
Pazopanib—MAP3K2—liver—atherosclerosis	0.000303	0.0046	CbGeAlD
Pazopanib—KIT—cardiovascular system—atherosclerosis	0.000303	0.0046	CbGeAlD
Pazopanib—MAP2K5—adipose tissue—atherosclerosis	0.000302	0.00457	CbGeAlD
Pazopanib—KDR—adipose tissue—atherosclerosis	0.000302	0.00457	CbGeAlD
Pazopanib—PDGFRB—cardiovascular system—atherosclerosis	0.000296	0.00449	CbGeAlD
Pazopanib—CSF1R—adipose tissue—atherosclerosis	0.000294	0.00446	CbGeAlD
Pazopanib—Oedema peripheral—Ezetimibe—atherosclerosis	0.000292	0.00355	CcSEcCtD
Pazopanib—Photosensitivity reaction—Pravastatin—atherosclerosis	0.000291	0.00354	CcSEcCtD
Pazopanib—Connective tissue disorder—Ezetimibe—atherosclerosis	0.000291	0.00354	CcSEcCtD
Pazopanib—Weight decreased—Pravastatin—atherosclerosis	0.000288	0.00351	CcSEcCtD
Pazopanib—FGF1—liver—atherosclerosis	0.000286	0.00433	CbGeAlD
Pazopanib—LCK—liver—atherosclerosis	0.000284	0.00431	CbGeAlD
Pazopanib—Jaundice—Niacin—atherosclerosis	0.000281	0.00343	CcSEcCtD
Pazopanib—Stomatitis—Niacin—atherosclerosis	0.000281	0.00343	CcSEcCtD
Pazopanib—Acute coronary syndrome—Pravastatin—atherosclerosis	0.00028	0.00341	CcSEcCtD
Pazopanib—Flushing—Lovastatin—atherosclerosis	0.00028	0.00341	CcSEcCtD
Pazopanib—Myocardial infarction—Pravastatin—atherosclerosis	0.000279	0.00339	CcSEcCtD
Pazopanib—Jaundice—Pravastatin—atherosclerosis	0.000277	0.00337	CcSEcCtD
Pazopanib—Flushing—Ezetimibe—atherosclerosis	0.000275	0.00334	CcSEcCtD
Pazopanib—Chills—Lovastatin—atherosclerosis	0.000271	0.0033	CcSEcCtD
Pazopanib—Cough—Rosuvastatin—atherosclerosis	0.00027	0.00329	CcSEcCtD
Pazopanib—FGFR2—liver—atherosclerosis	0.00027	0.00409	CbGeAlD
Pazopanib—Angiopathy—Ezetimibe—atherosclerosis	0.000269	0.00327	CcSEcCtD
Pazopanib—KIT—adipose tissue—atherosclerosis	0.000267	0.00405	CbGeAlD
Pazopanib—Mediastinal disorder—Ezetimibe—atherosclerosis	0.000267	0.00325	CcSEcCtD
Pazopanib—Alopecia—Lovastatin—atherosclerosis	0.000267	0.00325	CcSEcCtD
Pazopanib—Arthralgia—Rosuvastatin—atherosclerosis	0.000264	0.00321	CcSEcCtD
Pazopanib—Myalgia—Rosuvastatin—atherosclerosis	0.000264	0.00321	CcSEcCtD
Pazopanib—Flushing—Simvastatin—atherosclerosis	0.000262	0.00319	CcSEcCtD
Pazopanib—Alopecia—Ezetimibe—atherosclerosis	0.000262	0.00318	CcSEcCtD
Pazopanib—PDGFRB—adipose tissue—atherosclerosis	0.000261	0.00396	CbGeAlD
Pazopanib—Haemoglobin—Niacin—atherosclerosis	0.00026	0.00317	CcSEcCtD
Pazopanib—Mental disorder—Ezetimibe—atherosclerosis	0.000259	0.00316	CcSEcCtD
Pazopanib—Haemorrhage—Niacin—atherosclerosis	0.000259	0.00316	CcSEcCtD
Pazopanib—Flatulence—Lovastatin—atherosclerosis	0.000259	0.00315	CcSEcCtD
Pazopanib—Hypoaesthesia—Niacin—atherosclerosis	0.000258	0.00314	CcSEcCtD
Pazopanib—Erythema—Ezetimibe—atherosclerosis	0.000258	0.00314	CcSEcCtD
Pazopanib—Malnutrition—Ezetimibe—atherosclerosis	0.000258	0.00314	CcSEcCtD
Pazopanib—Dysgeusia—Lovastatin—atherosclerosis	0.000257	0.00313	CcSEcCtD
Pazopanib—Oedema peripheral—Niacin—atherosclerosis	0.000255	0.00311	CcSEcCtD
Pazopanib—Hypoaesthesia—Pravastatin—atherosclerosis	0.000254	0.00309	CcSEcCtD
Pazopanib—Flatulence—Ezetimibe—atherosclerosis	0.000254	0.00309	CcSEcCtD
Pazopanib—Chills—Simvastatin—atherosclerosis	0.000253	0.00308	CcSEcCtD
Pazopanib—Muscle spasms—Lovastatin—atherosclerosis	0.000253	0.00308	CcSEcCtD
Pazopanib—Infection—Rosuvastatin—atherosclerosis	0.000251	0.00306	CcSEcCtD
Pazopanib—FLT1—liver—atherosclerosis	0.00025	0.00379	CbGeAlD
Pazopanib—Alopecia—Simvastatin—atherosclerosis	0.000249	0.00304	CcSEcCtD
Pazopanib—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000248	0.00302	CcSEcCtD
Pazopanib—Muscle spasms—Ezetimibe—atherosclerosis	0.000248	0.00302	CcSEcCtD
Pazopanib—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000248	0.00302	CcSEcCtD
Pazopanib—Vision blurred—Lovastatin—atherosclerosis	0.000248	0.00301	CcSEcCtD
Pazopanib—Mental disorder—Simvastatin—atherosclerosis	0.000247	0.00301	CcSEcCtD
Pazopanib—Erythema—Simvastatin—atherosclerosis	0.000246	0.00299	CcSEcCtD
Pazopanib—Eye disorder—Niacin—atherosclerosis	0.000242	0.00295	CcSEcCtD
Pazopanib—Flatulence—Simvastatin—atherosclerosis	0.000242	0.00295	CcSEcCtD
Pazopanib—Dysgeusia—Simvastatin—atherosclerosis	0.000241	0.00293	CcSEcCtD
Pazopanib—Flushing—Niacin—atherosclerosis	0.000241	0.00293	CcSEcCtD
Pazopanib—Anaemia—Ezetimibe—atherosclerosis	0.000238	0.0029	CcSEcCtD
Pazopanib—STK10—liver—atherosclerosis	0.000237	0.00359	CbGeAlD
Pazopanib—Flushing—Pravastatin—atherosclerosis	0.000237	0.00288	CcSEcCtD
Pazopanib—Cardiac disorder—Pravastatin—atherosclerosis	0.000237	0.00288	CcSEcCtD
Pazopanib—Muscle spasms—Simvastatin—atherosclerosis	0.000236	0.00288	CcSEcCtD
Pazopanib—TAOK3—liver—atherosclerosis	0.000236	0.00358	CbGeAlD
Pazopanib—Angiopathy—Niacin—atherosclerosis	0.000235	0.00286	CcSEcCtD
Pazopanib—Leukopenia—Lovastatin—atherosclerosis	0.000235	0.00286	CcSEcCtD
Pazopanib—PDGFRA—liver—atherosclerosis	0.000234	0.00355	CbGeAlD
Pazopanib—Chills—Niacin—atherosclerosis	0.000233	0.00283	CcSEcCtD
Pazopanib—Vision blurred—Simvastatin—atherosclerosis	0.000232	0.00282	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00023	0.00281	CcSEcCtD
Pazopanib—Alopecia—Niacin—atherosclerosis	0.000229	0.00279	CcSEcCtD
Pazopanib—Chills—Pravastatin—atherosclerosis	0.000229	0.00279	CcSEcCtD
Pazopanib—Insomnia—Rosuvastatin—atherosclerosis	0.000229	0.00279	CcSEcCtD
Pazopanib—Paraesthesia—Rosuvastatin—atherosclerosis	0.000227	0.00277	CcSEcCtD
Pazopanib—Anaemia—Simvastatin—atherosclerosis	0.000227	0.00277	CcSEcCtD
Pazopanib—Erythema—Niacin—atherosclerosis	0.000226	0.00275	CcSEcCtD
Pazopanib—Malnutrition—Niacin—atherosclerosis	0.000226	0.00275	CcSEcCtD
Pazopanib—Alopecia—Pravastatin—atherosclerosis	0.000225	0.00275	CcSEcCtD
Pazopanib—Cough—Ezetimibe—atherosclerosis	0.000225	0.00274	CcSEcCtD
Pazopanib—UGT1A1—liver—atherosclerosis	0.000224	0.00339	CbGeAlD
Pazopanib—Arthralgia—Lovastatin—atherosclerosis	0.000224	0.00272	CcSEcCtD
Pazopanib—Chest pain—Lovastatin—atherosclerosis	0.000224	0.00272	CcSEcCtD
Pazopanib—Myalgia—Lovastatin—atherosclerosis	0.000224	0.00272	CcSEcCtD
Pazopanib—Dyspepsia—Rosuvastatin—atherosclerosis	0.000223	0.00271	CcSEcCtD
Pazopanib—Hypertension—Ezetimibe—atherosclerosis	0.000222	0.00271	CcSEcCtD
Pazopanib—Flatulence—Niacin—atherosclerosis	0.000222	0.00271	CcSEcCtD
Pazopanib—Leukopenia—Simvastatin—atherosclerosis	0.00022	0.00268	CcSEcCtD
Pazopanib—Chest pain—Ezetimibe—atherosclerosis	0.000219	0.00267	CcSEcCtD
Pazopanib—Myalgia—Ezetimibe—atherosclerosis	0.000219	0.00267	CcSEcCtD
Pazopanib—Arthralgia—Ezetimibe—atherosclerosis	0.000219	0.00267	CcSEcCtD
Pazopanib—Flatulence—Pravastatin—atherosclerosis	0.000219	0.00267	CcSEcCtD
Pazopanib—Dry mouth—Lovastatin—atherosclerosis	0.000219	0.00266	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000218	0.00265	CcSEcCtD
Pazopanib—Dysgeusia—Pravastatin—atherosclerosis	0.000218	0.00265	CcSEcCtD
Pazopanib—Muscle spasms—Niacin—atherosclerosis	0.000217	0.00264	CcSEcCtD
Pazopanib—Pain—Rosuvastatin—atherosclerosis	0.000216	0.00263	CcSEcCtD
Pazopanib—Dry mouth—Ezetimibe—atherosclerosis	0.000215	0.00261	CcSEcCtD
Pazopanib—Muscle spasms—Pravastatin—atherosclerosis	0.000214	0.0026	CcSEcCtD
Pazopanib—Infection—Lovastatin—atherosclerosis	0.000213	0.00259	CcSEcCtD
Pazopanib—Vision blurred—Niacin—atherosclerosis	0.000213	0.00259	CcSEcCtD
Pazopanib—KDR—liver—atherosclerosis	0.000212	0.00321	CbGeAlD
Pazopanib—MAP2K5—liver—atherosclerosis	0.000212	0.00321	CbGeAlD
Pazopanib—Thrombocytopenia—Lovastatin—atherosclerosis	0.00021	0.00256	CcSEcCtD
Pazopanib—Vision blurred—Pravastatin—atherosclerosis	0.000209	0.00255	CcSEcCtD
Pazopanib—Chest pain—Simvastatin—atherosclerosis	0.000209	0.00255	CcSEcCtD
Pazopanib—Arthralgia—Simvastatin—atherosclerosis	0.000209	0.00255	CcSEcCtD
Pazopanib—Myalgia—Simvastatin—atherosclerosis	0.000209	0.00255	CcSEcCtD
Pazopanib—Infection—Ezetimibe—atherosclerosis	0.000209	0.00254	CcSEcCtD
Pazopanib—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000207	0.00252	CcSEcCtD
Pazopanib—CSF1R—liver—atherosclerosis	0.000206	0.00313	CbGeAlD
Pazopanib—Nervous system disorder—Ezetimibe—atherosclerosis	0.000206	0.00251	CcSEcCtD
Pazopanib—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000206	0.00251	CcSEcCtD
Pazopanib—Anaemia—Pravastatin—atherosclerosis	0.000205	0.0025	CcSEcCtD
Pazopanib—Anorexia—Lovastatin—atherosclerosis	0.000204	0.00249	CcSEcCtD
Pazopanib—Skin disorder—Ezetimibe—atherosclerosis	0.000204	0.00249	CcSEcCtD
Pazopanib—Syncope—Niacin—atherosclerosis	0.000202	0.00246	CcSEcCtD
Pazopanib—Leukopenia—Niacin—atherosclerosis	0.000202	0.00246	CcSEcCtD
Pazopanib—Oedema—Simvastatin—atherosclerosis	0.000201	0.00244	CcSEcCtD
Pazopanib—Abdominal pain—Rosuvastatin—atherosclerosis	0.0002	0.00243	CcSEcCtD
Pazopanib—Infection—Simvastatin—atherosclerosis	0.000199	0.00243	CcSEcCtD
Pazopanib—Leukopenia—Pravastatin—atherosclerosis	0.000199	0.00242	CcSEcCtD
Pazopanib—Loss of consciousness—Niacin—atherosclerosis	0.000198	0.00241	CcSEcCtD
Pazopanib—Cough—Niacin—atherosclerosis	0.000197	0.0024	CcSEcCtD
Pazopanib—Thrombocytopenia—Simvastatin—atherosclerosis	0.000196	0.00239	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000195	0.00238	CcSEcCtD
Pazopanib—Insomnia—Lovastatin—atherosclerosis	0.000194	0.00236	CcSEcCtD
Pazopanib—Cough—Pravastatin—atherosclerosis	0.000194	0.00236	CcSEcCtD
Pazopanib—Paraesthesia—Lovastatin—atherosclerosis	0.000192	0.00234	CcSEcCtD
Pazopanib—Arthralgia—Niacin—atherosclerosis	0.000192	0.00234	CcSEcCtD
Pazopanib—Myalgia—Niacin—atherosclerosis	0.000192	0.00234	CcSEcCtD
Pazopanib—Hypertension—Pravastatin—atherosclerosis	0.000192	0.00234	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000192	0.00233	CcSEcCtD
Pazopanib—Anorexia—Simvastatin—atherosclerosis	0.000191	0.00233	CcSEcCtD
Pazopanib—Dyspnoea—Lovastatin—atherosclerosis	0.000191	0.00233	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000191	0.00232	CcSEcCtD
Pazopanib—Insomnia—Ezetimibe—atherosclerosis	0.00019	0.00232	CcSEcCtD
Pazopanib—Chest pain—Pravastatin—atherosclerosis	0.000189	0.0023	CcSEcCtD
Pazopanib—Arthralgia—Pravastatin—atherosclerosis	0.000189	0.0023	CcSEcCtD
Pazopanib—Myalgia—Pravastatin—atherosclerosis	0.000189	0.0023	CcSEcCtD
Pazopanib—Paraesthesia—Ezetimibe—atherosclerosis	0.000189	0.0023	CcSEcCtD
Pazopanib—Dyspepsia—Lovastatin—atherosclerosis	0.000189	0.0023	CcSEcCtD
Pazopanib—Dry mouth—Niacin—atherosclerosis	0.000188	0.00229	CcSEcCtD
Pazopanib—Dyspnoea—Ezetimibe—atherosclerosis	0.000187	0.00228	CcSEcCtD
Pazopanib—KIT—liver—atherosclerosis	0.000187	0.00284	CbGeAlD
Pazopanib—Decreased appetite—Lovastatin—atherosclerosis	0.000186	0.00227	CcSEcCtD
Pazopanib—SLCO1B1—liver—atherosclerosis	0.000186	0.00282	CbGeAlD
Pazopanib—Dyspepsia—Ezetimibe—atherosclerosis	0.000185	0.00225	CcSEcCtD
Pazopanib—Fatigue—Lovastatin—atherosclerosis	0.000185	0.00225	CcSEcCtD
Pazopanib—Oedema—Niacin—atherosclerosis	0.000184	0.00224	CcSEcCtD
Pazopanib—ABCB1—blood vessel—atherosclerosis	0.000184	0.00279	CbGeAlD
Pazopanib—Pain—Lovastatin—atherosclerosis	0.000183	0.00223	CcSEcCtD
Pazopanib—PDGFRB—liver—atherosclerosis	0.000183	0.00278	CbGeAlD
Pazopanib—Decreased appetite—Ezetimibe—atherosclerosis	0.000183	0.00223	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000183	0.00222	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000182	0.00221	CcSEcCtD
Pazopanib—Asthenia—Rosuvastatin—atherosclerosis	0.000181	0.00221	CcSEcCtD
Pazopanib—Insomnia—Simvastatin—atherosclerosis	0.000181	0.00221	CcSEcCtD
Pazopanib—Oedema—Pravastatin—atherosclerosis	0.000181	0.00221	CcSEcCtD
Pazopanib—Fatigue—Ezetimibe—atherosclerosis	0.000181	0.00221	CcSEcCtD
Pazopanib—Shock—Niacin—atherosclerosis	0.000181	0.00221	CcSEcCtD
Pazopanib—Infection—Pravastatin—atherosclerosis	0.00018	0.00219	CcSEcCtD
Pazopanib—Paraesthesia—Simvastatin—atherosclerosis	0.00018	0.00219	CcSEcCtD
Pazopanib—Pain—Ezetimibe—atherosclerosis	0.00018	0.00219	CcSEcCtD
Pazopanib—Pruritus—Rosuvastatin—atherosclerosis	0.000179	0.00218	CcSEcCtD
Pazopanib—Skin disorder—Niacin—atherosclerosis	0.000179	0.00218	CcSEcCtD
Pazopanib—Dyspnoea—Simvastatin—atherosclerosis	0.000179	0.00218	CcSEcCtD
Pazopanib—Hyperhidrosis—Niacin—atherosclerosis	0.000178	0.00217	CcSEcCtD
Pazopanib—Thrombocytopenia—Pravastatin—atherosclerosis	0.000177	0.00216	CcSEcCtD
Pazopanib—Dyspepsia—Simvastatin—atherosclerosis	0.000177	0.00215	CcSEcCtD
Pazopanib—Anorexia—Niacin—atherosclerosis	0.000176	0.00214	CcSEcCtD
Pazopanib—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000175	0.00213	CcSEcCtD
Pazopanib—Hyperhidrosis—Pravastatin—atherosclerosis	0.000175	0.00213	CcSEcCtD
Pazopanib—Decreased appetite—Simvastatin—atherosclerosis	0.000174	0.00212	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000173	0.00211	CcSEcCtD
Pazopanib—Diarrhoea—Rosuvastatin—atherosclerosis	0.000173	0.00211	CcSEcCtD
Pazopanib—Fatigue—Simvastatin—atherosclerosis	0.000173	0.00211	CcSEcCtD
Pazopanib—Anorexia—Pravastatin—atherosclerosis	0.000173	0.0021	CcSEcCtD
Pazopanib—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000172	0.00209	CcSEcCtD
Pazopanib—Pain—Simvastatin—atherosclerosis	0.000171	0.00209	CcSEcCtD
Pazopanib—Abdominal pain—Lovastatin—atherosclerosis	0.000169	0.00206	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000168	0.00204	CcSEcCtD
Pazopanib—Dizziness—Rosuvastatin—atherosclerosis	0.000167	0.00204	CcSEcCtD
Pazopanib—Insomnia—Niacin—atherosclerosis	0.000167	0.00203	CcSEcCtD
Pazopanib—Abdominal pain—Ezetimibe—atherosclerosis	0.000166	0.00202	CcSEcCtD
Pazopanib—Paraesthesia—Niacin—atherosclerosis	0.000165	0.00201	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000165	0.00201	CcSEcCtD
Pazopanib—Dyspnoea—Niacin—atherosclerosis	0.000164	0.002	CcSEcCtD
Pazopanib—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000164	0.002	CcSEcCtD
Pazopanib—Insomnia—Pravastatin—atherosclerosis	0.000164	0.002	CcSEcCtD
Pazopanib—Somnolence—Niacin—atherosclerosis	0.000164	0.00199	CcSEcCtD
Pazopanib—Paraesthesia—Pravastatin—atherosclerosis	0.000163	0.00198	CcSEcCtD
Pazopanib—Dyspepsia—Niacin—atherosclerosis	0.000162	0.00197	CcSEcCtD
Pazopanib—Dyspnoea—Pravastatin—atherosclerosis	0.000162	0.00197	CcSEcCtD
Pazopanib—Decreased appetite—Niacin—atherosclerosis	0.00016	0.00195	CcSEcCtD
Pazopanib—Dyspepsia—Pravastatin—atherosclerosis	0.00016	0.00194	CcSEcCtD
Pazopanib—Rash—Rosuvastatin—atherosclerosis	0.000159	0.00194	CcSEcCtD
Pazopanib—Dermatitis—Rosuvastatin—atherosclerosis	0.000159	0.00194	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Niacin—atherosclerosis	0.000159	0.00194	CcSEcCtD
Pazopanib—Abdominal pain—Simvastatin—atherosclerosis	0.000159	0.00193	CcSEcCtD
Pazopanib—Headache—Rosuvastatin—atherosclerosis	0.000158	0.00193	CcSEcCtD
Pazopanib—Decreased appetite—Pravastatin—atherosclerosis	0.000158	0.00192	CcSEcCtD
Pazopanib—Pain—Niacin—atherosclerosis	0.000157	0.00192	CcSEcCtD
Pazopanib—Fatigue—Pravastatin—atherosclerosis	0.000156	0.0019	CcSEcCtD
Pazopanib—Pain—Pravastatin—atherosclerosis	0.000155	0.00189	CcSEcCtD
Pazopanib—Asthenia—Lovastatin—atherosclerosis	0.000154	0.00187	CcSEcCtD
Pazopanib—Pruritus—Lovastatin—atherosclerosis	0.000152	0.00185	CcSEcCtD
Pazopanib—Asthenia—Ezetimibe—atherosclerosis	0.000151	0.00184	CcSEcCtD
Pazopanib—Gastrointestinal pain—Niacin—atherosclerosis	0.000151	0.00183	CcSEcCtD
Pazopanib—Nausea—Rosuvastatin—atherosclerosis	0.00015	0.00183	CcSEcCtD
Pazopanib—Pruritus—Ezetimibe—atherosclerosis	0.000149	0.00181	CcSEcCtD
Pazopanib—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000148	0.00181	CcSEcCtD
Pazopanib—ABCG2—adipose tissue—atherosclerosis	0.000147	0.00222	CbGeAlD
Pazopanib—Diarrhoea—Lovastatin—atherosclerosis	0.000147	0.00179	CcSEcCtD
Pazopanib—Abdominal pain—Niacin—atherosclerosis	0.000146	0.00177	CcSEcCtD
Pazopanib—Asthenia—Simvastatin—atherosclerosis	0.000144	0.00175	CcSEcCtD
Pazopanib—Diarrhoea—Ezetimibe—atherosclerosis	0.000144	0.00175	CcSEcCtD
Pazopanib—Abdominal pain—Pravastatin—atherosclerosis	0.000143	0.00175	CcSEcCtD
Pazopanib—Pruritus—Simvastatin—atherosclerosis	0.000142	0.00173	CcSEcCtD
Pazopanib—Dizziness—Lovastatin—atherosclerosis	0.000142	0.00173	CcSEcCtD
Pazopanib—Dizziness—Ezetimibe—atherosclerosis	0.000139	0.00169	CcSEcCtD
Pazopanib—Diarrhoea—Simvastatin—atherosclerosis	0.000137	0.00167	CcSEcCtD
Pazopanib—Vomiting—Lovastatin—atherosclerosis	0.000136	0.00166	CcSEcCtD
Pazopanib—Rash—Lovastatin—atherosclerosis	0.000135	0.00165	CcSEcCtD
Pazopanib—Dermatitis—Lovastatin—atherosclerosis	0.000135	0.00164	CcSEcCtD
Pazopanib—Headache—Lovastatin—atherosclerosis	0.000134	0.00164	CcSEcCtD
Pazopanib—Vomiting—Ezetimibe—atherosclerosis	0.000134	0.00163	CcSEcCtD
Pazopanib—Dizziness—Simvastatin—atherosclerosis	0.000133	0.00161	CcSEcCtD
Pazopanib—Rash—Ezetimibe—atherosclerosis	0.000133	0.00161	CcSEcCtD
Pazopanib—Dermatitis—Ezetimibe—atherosclerosis	0.000132	0.00161	CcSEcCtD
Pazopanib—Asthenia—Niacin—atherosclerosis	0.000132	0.00161	CcSEcCtD
Pazopanib—Headache—Ezetimibe—atherosclerosis	0.000132	0.0016	CcSEcCtD
Pazopanib—Pruritus—Niacin—atherosclerosis	0.00013	0.00159	CcSEcCtD
Pazopanib—Asthenia—Pravastatin—atherosclerosis	0.00013	0.00158	CcSEcCtD
Pazopanib—Pruritus—Pravastatin—atherosclerosis	0.000128	0.00156	CcSEcCtD
Pazopanib—Vomiting—Simvastatin—atherosclerosis	0.000127	0.00155	CcSEcCtD
Pazopanib—Nausea—Lovastatin—atherosclerosis	0.000127	0.00155	CcSEcCtD
Pazopanib—Rash—Simvastatin—atherosclerosis	0.000126	0.00154	CcSEcCtD
Pazopanib—Dermatitis—Simvastatin—atherosclerosis	0.000126	0.00154	CcSEcCtD
Pazopanib—Diarrhoea—Niacin—atherosclerosis	0.000126	0.00153	CcSEcCtD
Pazopanib—Headache—Simvastatin—atherosclerosis	0.000126	0.00153	CcSEcCtD
Pazopanib—Nausea—Ezetimibe—atherosclerosis	0.000125	0.00152	CcSEcCtD
Pazopanib—Diarrhoea—Pravastatin—atherosclerosis	0.000124	0.00151	CcSEcCtD
Pazopanib—Dizziness—Niacin—atherosclerosis	0.000122	0.00148	CcSEcCtD
Pazopanib—Dizziness—Pravastatin—atherosclerosis	0.00012	0.00146	CcSEcCtD
Pazopanib—Nausea—Simvastatin—atherosclerosis	0.000119	0.00145	CcSEcCtD
Pazopanib—Vomiting—Niacin—atherosclerosis	0.000117	0.00143	CcSEcCtD
Pazopanib—Rash—Niacin—atherosclerosis	0.000116	0.00141	CcSEcCtD
Pazopanib—Dermatitis—Niacin—atherosclerosis	0.000116	0.00141	CcSEcCtD
Pazopanib—Headache—Niacin—atherosclerosis	0.000115	0.0014	CcSEcCtD
Pazopanib—Vomiting—Pravastatin—atherosclerosis	0.000115	0.0014	CcSEcCtD
Pazopanib—Rash—Pravastatin—atherosclerosis	0.000114	0.00139	CcSEcCtD
Pazopanib—Dermatitis—Pravastatin—atherosclerosis	0.000114	0.00139	CcSEcCtD
Pazopanib—Headache—Pravastatin—atherosclerosis	0.000114	0.00138	CcSEcCtD
Pazopanib—Nausea—Niacin—atherosclerosis	0.000109	0.00133	CcSEcCtD
Pazopanib—Nausea—Pravastatin—atherosclerosis	0.000108	0.00131	CcSEcCtD
Pazopanib—CYP2C8—liver—atherosclerosis	0.000106	0.0016	CbGeAlD
Pazopanib—ABCG2—liver—atherosclerosis	0.000103	0.00156	CbGeAlD
Pazopanib—CYP1A2—liver—atherosclerosis	9.9e-05	0.0015	CbGeAlD
Pazopanib—ABCB1—cardiovascular system—atherosclerosis	8.2e-05	0.00124	CbGeAlD
Pazopanib—ABCB1—adipose tissue—atherosclerosis	7.23e-05	0.0011	CbGeAlD
Pazopanib—CYP3A4—liver—atherosclerosis	7.17e-05	0.00109	CbGeAlD
Pazopanib—CYP2D6—liver—atherosclerosis	7.05e-05	0.00107	CbGeAlD
Pazopanib—ABCB1—liver—atherosclerosis	5.07e-05	0.000769	CbGeAlD
Pazopanib—CYP3A4—Metabolism—LPA—atherosclerosis	2.03e-06	1.86e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CETP—atherosclerosis	2.02e-06	1.85e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—F2—atherosclerosis	2.02e-06	1.85e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—HMOX1—atherosclerosis	2.01e-06	1.84e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—NOS3—atherosclerosis	2.01e-06	1.84e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—PTGS2—atherosclerosis	2e-06	1.83e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—TGFB1—atherosclerosis	2e-06	1.83e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—NOS3—atherosclerosis	2e-06	1.83e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CXCL8—atherosclerosis	1.97e-06	1.8e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—NFKB1—atherosclerosis	1.97e-06	1.8e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—BGN—atherosclerosis	1.97e-06	1.8e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CXCL8—atherosclerosis	1.97e-06	1.8e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—MAPK3—atherosclerosis	1.97e-06	1.8e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—AKT1—atherosclerosis	1.96e-06	1.79e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—NOS3—atherosclerosis	1.96e-06	1.79e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—APOA5—atherosclerosis	1.95e-06	1.78e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—MAPK3—atherosclerosis	1.95e-06	1.78e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—ALB—atherosclerosis	1.94e-06	1.78e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—MAPK8—atherosclerosis	1.94e-06	1.77e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—SCARB1—atherosclerosis	1.93e-06	1.77e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PIK3CG—atherosclerosis	1.93e-06	1.77e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—APOB—atherosclerosis	1.92e-06	1.76e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ABCA1—atherosclerosis	1.92e-06	1.76e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MMP9—atherosclerosis	1.91e-06	1.75e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—TGFB1—atherosclerosis	1.91e-06	1.74e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—NFKB1—atherosclerosis	1.89e-06	1.73e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—AKT1—atherosclerosis	1.89e-06	1.73e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—TGFB1—atherosclerosis	1.89e-06	1.73e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	1.88e-06	1.72e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MMP9—atherosclerosis	1.88e-06	1.72e-05	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—AKT1—atherosclerosis	1.88e-06	1.72e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	1.88e-06	1.72e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—GSTM1—atherosclerosis	1.87e-06	1.71e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MAPK8—atherosclerosis	1.86e-06	1.7e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—NFKB1—atherosclerosis	1.86e-06	1.7e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—NOS3—atherosclerosis	1.86e-06	1.7e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—IL6—atherosclerosis	1.84e-06	1.68e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—LPL—atherosclerosis	1.84e-06	1.68e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PTGS2—atherosclerosis	1.84e-06	1.68e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—INS—atherosclerosis	1.83e-06	1.67e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MAPK8—atherosclerosis	1.83e-06	1.67e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—HMGCR—atherosclerosis	1.83e-06	1.67e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ALOX5—atherosclerosis	1.81e-06	1.66e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—IL6—atherosclerosis	1.81e-06	1.65e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CCL2—atherosclerosis	1.8e-06	1.65e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—GPX1—atherosclerosis	1.79e-06	1.64e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MMP9—atherosclerosis	1.78e-06	1.63e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MMP9—atherosclerosis	1.78e-06	1.63e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CXCL8—atherosclerosis	1.77e-06	1.62e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—STAT3—atherosclerosis	1.77e-06	1.62e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IGF1—atherosclerosis	1.77e-06	1.62e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—NFKB1—atherosclerosis	1.77e-06	1.62e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—NFKB1—atherosclerosis	1.76e-06	1.61e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—HMOX1—atherosclerosis	1.75e-06	1.6e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—CD36—atherosclerosis	1.75e-06	1.6e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CXCL8—atherosclerosis	1.74e-06	1.59e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MAPK8—atherosclerosis	1.74e-06	1.59e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MAPK8—atherosclerosis	1.73e-06	1.58e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—IL6—atherosclerosis	1.73e-06	1.58e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—VEGFA—atherosclerosis	1.72e-06	1.57e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—IL6—atherosclerosis	1.71e-06	1.57e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—IL6—atherosclerosis	1.71e-06	1.56e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—STAT3—atherosclerosis	1.7e-06	1.56e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PTGS2—atherosclerosis	1.7e-06	1.55e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—IL6—atherosclerosis	1.7e-06	1.55e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—AKT1—atherosclerosis	1.7e-06	1.55e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—MAPK3—atherosclerosis	1.69e-06	1.55e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—VEGFA—atherosclerosis	1.69e-06	1.54e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—SERPINE1—atherosclerosis	1.68e-06	1.54e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—APOB—atherosclerosis	1.68e-06	1.53e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—STAT3—atherosclerosis	1.67e-06	1.53e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—IL6—atherosclerosis	1.67e-06	1.53e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—AKT1—atherosclerosis	1.67e-06	1.52e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—MTHFR—atherosclerosis	1.65e-06	1.51e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—HMOX1—atherosclerosis	1.65e-06	1.51e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	1.65e-06	1.51e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—STAT3—atherosclerosis	1.63e-06	1.49e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—GSTM1—atherosclerosis	1.63e-06	1.49e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ABCA1—atherosclerosis	1.63e-06	1.49e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MAPK3—atherosclerosis	1.63e-06	1.49e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—NAMPT—atherosclerosis	1.63e-06	1.49e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PPARA—atherosclerosis	1.62e-06	1.48e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—LIPC—atherosclerosis	1.62e-06	1.48e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—APOC3—atherosclerosis	1.61e-06	1.47e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—NOS3—atherosclerosis	1.6e-06	1.47e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MMP9—atherosclerosis	1.6e-06	1.47e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—VEGFA—atherosclerosis	1.6e-06	1.47e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—LPL—atherosclerosis	1.6e-06	1.46e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—VEGFA—atherosclerosis	1.6e-06	1.46e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MAPK3—atherosclerosis	1.6e-06	1.46e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—LDLR—atherosclerosis	1.6e-06	1.46e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—AKT1—atherosclerosis	1.6e-06	1.46e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—STAT3—atherosclerosis	1.59e-06	1.45e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—NFKB1—atherosclerosis	1.59e-06	1.45e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—IL6—atherosclerosis	1.58e-06	1.45e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—STAT3—atherosclerosis	1.58e-06	1.45e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—AKT1—atherosclerosis	1.58e-06	1.45e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—APOB—atherosclerosis	1.58e-06	1.44e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—IL6—atherosclerosis	1.58e-06	1.44e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TGFB1—atherosclerosis	1.58e-06	1.44e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—AKT1—atherosclerosis	1.58e-06	1.44e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—AGT—atherosclerosis	1.57e-06	1.44e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MMP9—atherosclerosis	1.57e-06	1.44e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—AKT1—atherosclerosis	1.57e-06	1.43e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—MAPK3—atherosclerosis	1.56e-06	1.43e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—GPX1—atherosclerosis	1.56e-06	1.43e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MAPK8—atherosclerosis	1.56e-06	1.43e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CETP—atherosclerosis	1.56e-06	1.43e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—NFKB1—atherosclerosis	1.55e-06	1.42e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TGFB1—atherosclerosis	1.55e-06	1.42e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—IL6—atherosclerosis	1.55e-06	1.41e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—IL6—atherosclerosis	1.54e-06	1.41e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—APOE—atherosclerosis	1.54e-06	1.41e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—AKT1—atherosclerosis	1.54e-06	1.41e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—GSTM1—atherosclerosis	1.54e-06	1.41e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MAPK8—atherosclerosis	1.53e-06	1.4e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—CAV1—atherosclerosis	1.53e-06	1.4e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—APOA1—atherosclerosis	1.52e-06	1.39e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—CD36—atherosclerosis	1.52e-06	1.39e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MAPK3—atherosclerosis	1.52e-06	1.39e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—TGFB1—atherosclerosis	1.51e-06	1.39e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MAPK3—atherosclerosis	1.51e-06	1.38e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—IL6—atherosclerosis	1.51e-06	1.38e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—LPL—atherosclerosis	1.51e-06	1.38e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—IL6—atherosclerosis	1.51e-06	1.38e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—SCARB1—atherosclerosis	1.49e-06	1.37e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—GPX1—atherosclerosis	1.47e-06	1.35e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TGFB1—atherosclerosis	1.47e-06	1.35e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TGFB1—atherosclerosis	1.47e-06	1.34e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—AKT1—atherosclerosis	1.46e-06	1.34e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—AKT1—atherosclerosis	1.46e-06	1.33e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—MTHFR—atherosclerosis	1.44e-06	1.32e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—VEGFA—atherosclerosis	1.44e-06	1.32e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—IL6—atherosclerosis	1.44e-06	1.31e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CD36—atherosclerosis	1.43e-06	1.31e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—AKT1—atherosclerosis	1.43e-06	1.3e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—STAT3—atherosclerosis	1.43e-06	1.3e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CXCL8—atherosclerosis	1.42e-06	1.3e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—IL6—atherosclerosis	1.42e-06	1.3e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—AKT1—atherosclerosis	1.42e-06	1.3e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PPARA—atherosclerosis	1.41e-06	1.29e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—VEGFA—atherosclerosis	1.41e-06	1.29e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—HMGCR—atherosclerosis	1.41e-06	1.29e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—HMOX1—atherosclerosis	1.4e-06	1.28e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—STAT3—atherosclerosis	1.4e-06	1.28e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—AKT1—atherosclerosis	1.39e-06	1.27e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—AKT1—atherosclerosis	1.39e-06	1.27e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CG—atherosclerosis	1.39e-06	1.27e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—AGT—atherosclerosis	1.37e-06	1.25e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MAPK3—atherosclerosis	1.36e-06	1.25e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—MTHFR—atherosclerosis	1.36e-06	1.24e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—APOE—atherosclerosis	1.34e-06	1.23e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PPARG—atherosclerosis	1.34e-06	1.23e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—APOB—atherosclerosis	1.34e-06	1.22e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MAPK3—atherosclerosis	1.33e-06	1.22e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PPARA—atherosclerosis	1.33e-06	1.22e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—CAV1—atherosclerosis	1.33e-06	1.22e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—APOA1—atherosclerosis	1.33e-06	1.21e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—AKT1—atherosclerosis	1.33e-06	1.21e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TGFB1—atherosclerosis	1.32e-06	1.21e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—INS—atherosclerosis	1.32e-06	1.2e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—AKT1—atherosclerosis	1.31e-06	1.2e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GSTM1—atherosclerosis	1.3e-06	1.19e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TGFB1—atherosclerosis	1.29e-06	1.18e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—AGT—atherosclerosis	1.29e-06	1.18e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MMP9—atherosclerosis	1.29e-06	1.18e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—LPL—atherosclerosis	1.28e-06	1.17e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—NFKB1—atherosclerosis	1.27e-06	1.16e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—APOE—atherosclerosis	1.26e-06	1.16e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ABCA1—atherosclerosis	1.26e-06	1.15e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CAV1—atherosclerosis	1.25e-06	1.15e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MAPK8—atherosclerosis	1.25e-06	1.14e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—APOA1—atherosclerosis	1.25e-06	1.14e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GPX1—atherosclerosis	1.25e-06	1.14e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—IL6—atherosclerosis	1.24e-06	1.13e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CD36—atherosclerosis	1.21e-06	1.11e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CG—atherosclerosis	1.21e-06	1.11e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—ALB—atherosclerosis	1.21e-06	1.1e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—IL6—atherosclerosis	1.19e-06	1.09e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PPARG—atherosclerosis	1.17e-06	1.07e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—IL6—atherosclerosis	1.17e-06	1.07e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—VEGFA—atherosclerosis	1.16e-06	1.06e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—NOS3—atherosclerosis	1.15e-06	1.06e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—MTHFR—atherosclerosis	1.15e-06	1.05e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—INS—atherosclerosis	1.15e-06	1.05e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—STAT3—atherosclerosis	1.14e-06	1.05e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—IL6—atherosclerosis	1.14e-06	1.04e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CG—atherosclerosis	1.14e-06	1.04e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—AKT1—atherosclerosis	1.14e-06	1.04e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PPARA—atherosclerosis	1.13e-06	1.03e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—IL6—atherosclerosis	1.11e-06	1.01e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IL6—atherosclerosis	1.11e-06	1.01e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PPARG—atherosclerosis	1.1e-06	1.01e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—AKT1—atherosclerosis	1.1e-06	1e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MAPK3—atherosclerosis	1.09e-06	1e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—AGT—atherosclerosis	1.09e-06	1e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—INS—atherosclerosis	1.08e-06	9.88e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—HMOX1—atherosclerosis	1.08e-06	9.86e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—AKT1—atherosclerosis	1.08e-06	9.86e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—APOE—atherosclerosis	1.07e-06	9.79e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CAV1—atherosclerosis	1.06e-06	9.7e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TGFB1—atherosclerosis	1.06e-06	9.7e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—APOA1—atherosclerosis	1.06e-06	9.68e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PTGS2—atherosclerosis	1.05e-06	9.65e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—AKT1—atherosclerosis	1.05e-06	9.63e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—ALB—atherosclerosis	1.05e-06	9.61e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—APOB—atherosclerosis	1.03e-06	9.44e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—AKT1—atherosclerosis	1.02e-06	9.35e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—AKT1—atherosclerosis	1.02e-06	9.33e-06	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—AKT1—atherosclerosis	1.01e-06	9.21e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—NOS3—atherosclerosis	1e-06	9.19e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GSTM1—atherosclerosis	1e-06	9.19e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IL6—atherosclerosis	9.96e-07	9.11e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ALB—atherosclerosis	9.9e-07	9.05e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—LPL—atherosclerosis	9.86e-07	9.02e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IL6—atherosclerosis	9.75e-07	8.92e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CG—atherosclerosis	9.66e-07	8.84e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GPX1—atherosclerosis	9.62e-07	8.8e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—NOS3—atherosclerosis	9.47e-07	8.66e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CD36—atherosclerosis	9.37e-07	8.57e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PPARG—atherosclerosis	9.33e-07	8.53e-06	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—AKT1—atherosclerosis	9.23e-07	8.44e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PTGS2—atherosclerosis	9.19e-07	8.41e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—AKT1—atherosclerosis	9.19e-07	8.41e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—INS—atherosclerosis	9.15e-07	8.37e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—AKT1—atherosclerosis	9e-07	8.23e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—MTHFR—atherosclerosis	8.88e-07	8.12e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PPARA—atherosclerosis	8.71e-07	7.97e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PTGS2—atherosclerosis	8.66e-07	7.92e-06	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—AKT1—atherosclerosis	8.54e-07	7.81e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—AGT—atherosclerosis	8.43e-07	7.71e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ALB—atherosclerosis	8.39e-07	7.67e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—APOE—atherosclerosis	8.26e-07	7.56e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CAV1—atherosclerosis	8.19e-07	7.49e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—APOA1—atherosclerosis	8.17e-07	7.47e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—NOS3—atherosclerosis	8.02e-07	7.34e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IL6—atherosclerosis	7.99e-07	7.31e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CG—atherosclerosis	7.46e-07	6.82e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—AKT1—atherosclerosis	7.37e-07	6.75e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PTGS2—atherosclerosis	7.34e-07	6.71e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PPARG—atherosclerosis	7.2e-07	6.58e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—INS—atherosclerosis	7.06e-07	6.46e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ALB—atherosclerosis	6.47e-07	5.92e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—NOS3—atherosclerosis	6.19e-07	5.66e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PTGS2—atherosclerosis	5.66e-07	5.18e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—AKT1—atherosclerosis	5.3e-07	4.85e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—AKT1—atherosclerosis	4.62e-07	4.23e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—AKT1—atherosclerosis	4.35e-07	3.98e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—AKT1—atherosclerosis	3.69e-07	3.37e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—AKT1—atherosclerosis	2.85e-07	2.6e-06	CbGpPWpGaD
